The leading company in the marijuana industry, Aurora Cannabis, has now reached a milestone in international lands. The German authorities have granted the company an important certification for its medical cannabis cultivation facility of more than 3,500 square meters.
The news was announced yesterday when the Edmonton-based company said that it now holds an EU-GMP certificate for its medical production facility in Germany. The German Federal Institute for Drugs and Medical Devices (BfArM) was the entity that awarded the honors to Aurora.
The facility located in Leuna, Saxony-Anhalt, Germany, is an essential tool for the company to supply high-quality cannabis flowers and extracts for medical use by patients. Existing markets currently serve nearly 100,000 Germans, and some of that demand has been met thanks to the operations Aurora runs at this facility.
Three years ago, Aurora was awarded a contract by the German Federal Institute for Drugs and Medical Devices. The deal gave the company the ability to produce 1,000 kilograms of dried flower annually over a four-year period. The first shipment is expected to proceed later this month through the state’s cannabis agency.
“With the EU-GMP certification of our first German site, we once again demonstrate Aurora’s excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market,” Aurora CEO Miguel Martin said in a statement. “As a leading provider of medical cannabis in Germany and several other European markets, we are eager to accelerate patient access to high-quality, reliable cannabis produced in accordance with the most stringent criteria.”
It has been made clear that the shipment from this first-class facility will serve to broaden the patient base, becoming a way to pave the way for the company’s continued commitment to international market growth. The company continues to make great strides to have an extensive footprint both within and beyond its borders.